Subscribe To
APRE / Aprea Therapeutics (APRE) Stock Soars as Wedbush Sets $3 Price Target
APRE News
By Zacks Investment Research
April 4, 2023
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal
By InvestorPlace
July 8, 2022
Aprea Therapeutics (APRE) Stock Soars as Wedbush Sets $3 Price Target
Wedbush analyst Robert Driscoll just gave a huge upside target for APRE stock. Here's why this is significant for the biotech sector. more_horizontal